BACKGROUND & AIMS: Acute liver failure (ALF) is defined as rapid onset coagulopathy and encephalopathy in patients without a prior history of liver disease. We performed untargeted and targeted serum proteomics to delineate processes occurring in adult patients with ALF and to identify potential biomarkers. METHODS: Sera of 319 adult patients with ALF (∼50% acetaminophen [APAP]-related cases) were randomly selected from admission samples of the multicenter USA Acute Liver Failure Study Group consortium and subdivided into discovery/validation cohorts. They were analyzed using untargeted proteomics with mass spectroscopy and a serum cytokine profiling and compared with 30 healthy controls. The primary clinical outcome was 21-day transplant-free survival. Single-cell RNAseq data mapped biomarkers to cells of origin; functional enrichment analysis provided mechanistic insights. Novel prognostic scores were compared with the model for end-stage liver disease and ALFSG prognostic index scores. RESULTS: In the discovery cohort, 117 proteins differed between patients with ALF and healthy controls. There were 167 proteins associated with APAP-related ALF, with the majority being hepatocyte-derived. Three hepatocellular proteins (ALDOB, CAT, and PIGR) robustly and reproducibly discriminated APAP from non-APAP cases (AUROCs ∼0.9). In the discovery cohort, 37 proteins were related to 21-day outcome. The key processes associated with survival were acute-phase response and hepatocyte nuclear factor 1α signaling. SERPINA1 and LRG1 were the best individual discriminators of 21-day transplant-free survival in both cohorts. Two models of blood-based proteomic biomarkers outperformed the model for end-stage liver disease and ALFSG prognostic index and were reproduced in the validation cohort (AUROCs 0.83-0.86) for 21-day transplant-free survival. CONCLUSIONS: Proteomics and cytokine profiling identified new, reproducible biomarkers associated with APAP etiology and 21-day outcome. These biomarkers may improve prognostication and understanding of the etiopathogenesis of ALF but need to be independently validated. IMPACT AND IMPLICATIONS: Acute liver failure (ALF) is a sudden, and severe condition associated with high fatality. More sensitive and specific prognostic scores are urgently needed to facilitate decision-making regarding liver transplantation in patients with ALF. Our proteomic analysis uncovered marked differences between acetaminophen and non-acetaminophen-related ALF. The identification of routinely measurable biomarkers that are associated with 21-day transplant-free survival and the derivation of novel prognostic scores may facilitate clinical management as well as decisions for/against liver transplantation. Further studies are needed to quantify less abundant proteins. Although we used two cohorts, our findings still need to be independently and prospectively validated.

Department of Critical Care Medicine University of Alberta Edmonton AB Canada

Department of Econometrics Prague University of Economics and Business Prague Czechia

Department of Gastroenterology Hepatology Infectious Diseases and Endocrinology Hannover Medical School Hannover Germany

Department of Hepatology and Gastroenterology Charité Universitätsmedizin Campus Charité Mitte and Campus Virchow Klinikum Berlin Germany

Department of Internal Medicine Division of Digestive and Liver Diseases UT Southwestern Medical Center Dallas TX USA

Department of Internal Medicine Division of Gastroenterology University of Michigan Ann Arbor MI USA

Department of Molecular Systems Biology Helmholtz Centre for Environmental Research Leipzig Germany

Department of Public Health Sciences Medical University of South Carolina Charleston SC USA

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Frankfurt am Main Germany

Goethe University Institute of Clinical Pharmacology Frankfurt am Main Germany

Medical Clinic 3 Gastroenterology Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Health Care Provider of the European Reference Network on Rare Liver Disorders Aachen Germany

Zobrazit více v PubMed

Stravitz R.T., Lee W.M. Acute liver failure. Lancet. 2019;394:869–881. PubMed PMC

European Association for the Study of the Liver EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–1081. PubMed

McPhail M.J.W., Farne H., Senvar N., et al. Ability of King’s College Criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: a meta-analysis. Clin Gastroenterol Hepatol. 2016;14:516–525.e5. PubMed

Koch D.G., Tillman H., Durkalski V., et al. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14:1199. 206.e2. PubMed PMC

Tavabie O.D., Karvellas C.J., Salehi S., et al. A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure. J Hepatol. 2021;75:424–434. PubMed PMC

Kuscuoglu D., Janciauskiene S., Hamesch K., et al. Liver – master and servant of serum proteome. J Hepatol. 2018;69:512–524. PubMed

Tacke F., Luedde T., Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol. 2009;36:4–12. PubMed

Rutherford A., King L.Y., Hynan L.S., et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology. 2012;143:1237–1243. PubMed PMC

Spivak I., Arora J., Meinzer C., et al. Low serum hepcidin is associated with reduced short-term survival in adults with acute liver failure. Hepatology. 2019;69:2136–2149. PubMed

Hamesch K., Mandorfer M., Pereira V.M., et al. Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi∗ZZ mutation. Gastroenterology. 2019;157:705. 19.e18. PubMed

Wei R., Wang J., Su M., et al. Missing value imputation approach for mass spectrometry-based metabolomics data. Sci Rep. 2018;8:1–10. PubMed PMC

Niu L., Geyer P.E., Wewer Albrechtsen N.J., et al. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol. 2019;15:1–16. PubMed PMC

Gurbuz B., Guldiken N., Reuken P., et al. Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis. Hepatol Int. 2023;17:698–708. PubMed PMC

Åkesson J., Hojjati S., Hellberg S., et al. Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nat Commun. 2023;14:6903. PubMed PMC

Cohen J. 2nd ed. Routledge; 1988. Statistical power analysis for the behavioral sciences.

Skates S.J., Gillette M.A., LaBaer J., et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12:5383–5394. PubMed PMC

Team RC R: a language and environment for statistical computing. 2021. https://www.r-project.org/

RStudio Team RStudio: integrated development environment for R. 2023. https://posit.co

Lazar C., Burger T. imputeLCMD: a collection of methods for left-censored missing data imputation. 2022. https://cran.r-project.org/package=imputeLCMD

Morgan M., Obenchain V., Hester J., et al. 2021. SummarizedExperiment: SummarizedExperiment container. [ductor.org/packages/SummarizedExperiment]

Ritchie M.E., Phipson B., Wu D., et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43 PubMed PMC

Gu Z., Eils R., Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847–2849. PubMed

Gu Z. Complex heatmap visualization. iMeta. 2022;1:1–15. PubMed PMC

Gu Z., Gu L., Eils R., et al. Circlize implements and enhances circular visualization in R. Bioinformatics. 2014;30:2811–2812. PubMed

Friedman J., Hastie T., Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22. PubMed PMC

Tay J.K., Narasimhan B., Hastie T. Elastic net regularization paths for all generalized linear models. J Stat Softw. 2023;106 PubMed PMC

Robin X., Turck N., Hainard A., et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;8:12–77. PubMed PMC

Wei T., Simko V. R package ‘corrplot’: Visualization of a correlation matrix(Version 0.95) 2024. https://github.com/taiyun/corrplot

DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845. PubMed

Moreira M.J. A conditional likelihood ratio test for structural models. Econometrica. 2003;71:1027–1048.

Collins G.S., Reitsma J.B., Altman D.G., et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 2015;13:1–10. PubMed PMC

Hughes R.D., Zhang L., Tsubouchi H., et al. Plasma hepatocyte growth factor and biliprotein levels and outcome in fulminant hepatic failure. J Hepatol. 1994;20:106–111. PubMed

Shirai R., Hirano F., Ohkura N., et al. Up-regulation of the expression of leucine-rich α2-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun. 2009;382:776–779. PubMed PMC

Hugenholtz G.C.G., Adelmeijer J., Meijers J.C.M., et al. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology. 2013;58:752–761. PubMed

Ferlitsch M., Reiberger T., Hoke M., et al. Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56:1439–1447. PubMed

Ravindra K.C., Vaidya V.S., Wang Z., et al. Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. Nat Commun. 2023;14:1–14. PubMed PMC

Asaka M., Miyazaki T., Hollinger F.B., et al. Human aldolase B serum levels: a marker of liver injury. Hepatology. 1984;4:531–535. PubMed

Argemi J., Latasa M.U., Atkinson S.R., et al. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun. 2019;10:3126. PubMed PMC

Sander L.E., Sackett S.D., Dierssen U., et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453–1464. PubMed PMC

Wang X., Abraham S., McKenzie J.A.G., et al. LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature. 2013;499:306–311. PubMed PMC

Strnad P., McElvaney N.G., Lomas D.A. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;38:1443–1455. PubMed

Cressman D.E., Greenbaum L.E., DeAngelis R.A., et al. Liver failure and defective hepatocyte regeneration in interleukin-6- deficient mice. Science. 1996;274:1379–1383. PubMed

Blindenbacher A., Wang X., Langer I., et al. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology. 2003;38:674–682. PubMed

Bonkovsky H.L., Barnhart H.X., Foureau D.M., et al. Cytokine profiles in acute liver injury—results from the US drug-induced liver injury network (DILIN) and the acute liver failure study group. PLoS One. 2018;13:1–20. PubMed PMC

Glavind E., Gotthardt D.N., Pfeiffenberger J., et al. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease. Orphanet J Rare Dis. 2020;15:1–9. PubMed PMC

Vazquez J.H., Kennon-Mcgill S., Byrum S.D., et al. Proteomics indicates lactate dehydrogenase is prognostic in acetaminophen-induced acute liver failure patients and reveals altered signaling pathways. Toxicol Sci. 2022;187:25–34. PubMed PMC

Kwan R., Chen L., Park M.J., et al. The role of carbamoyl phosphate synthetase 1 as a prognostic biomarker in patients with acetaminophen-induced acute liver failure. Clin Gastroenterol Hepatol. 2023;21:3060. 9.e8. PubMed PMC